RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial – JAMA (free for a limited period)

Editorials:

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed? – JAMA (free for a limited period)

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease – JAMA (free for a limited period)

Ushering in a New Era of Alzheimer Disease Therapy – JAMA (free for a limited period)

See also: Visual Abstract

Commentary: Expert reaction to results from Eli Lilly on its anti-amyloid drug donanemab – Science Media Centre

Related: RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.